ArticleVaccine2010
Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Low-Frequency, Sustained CD4 T-Cell Responses Chlamydia trachomatis in Women: Predominant Targeting of Chlamydial Proteaselike Activity Factor (CPAF).The Journal of infectious diseases · 2025Article
- Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.Mucosal immunology · 2024Article
- Efficacy of Pgp3 vaccination forFrontiers in immunology · 2022Article
- Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-BasedFrontiers in immunology · 2021Article
- Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.Immunology and cell biology · 2019Article
- Update on Chlamydia trachomatis Vaccinology.Clinical and vaccine immunology : CVI · 2017Review
- TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models.Oncoimmunology · 2016Article
- Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates.Virulence · 2016Review
- Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis.Human vaccines & immunotherapeutics · 2014Review
- A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.Vaccine · 2013Article
- Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model.PLoS neglected tropical diseases · 2013Article
- Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.Infection and immunity · 2012Article
- Article
- Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Infection and immunity · 2011Review
- Article
- Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection.Current opinion in infectious diseases · 2011Review
- Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.Infection and immunity · 2010Article
- Role of route of delivery on Chlamydia abortus vaccine-induced immune responses and genital tract immunity in mice.Microbes and infectionArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
We have shown previously that vaccination with recombinant chlamydial protease-like activity factor (rCPAF) plus interleukin-12 as an adjuvant induces robust protective immunity against primary genital Chlamydia muridarum challenge in mice. Since CPAF is a protease, we compared the effects of enzymatically active and inactive (heat denatured) rCPAF to determine whether proteolytic activity is expendable for the induction of protective immunity against chlamydial challenge. Active, but not inactive, rCPAF immunization induced high levels of anti-active CPAF antibody, whereas both induced robust splenic CPAF-specific IFN-gamma production. Vaccination with active or inactive rCPAF induced enhanced vaginal chlamydial clearance as early as day 6 with complete resolution of infection by day 18, compared to day 30 in mock-vaccinated and challenged animals. Importantly, significant and comparable reductions in oviduct pathology were observed in active and inactive rCPAF-vaccinated mice compared to mock-vaccinated animals. Thus, rCPAF induced anti-chlamydial immunity is largely independent of enzymatic activity and secondary or higher order protein conformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.